[en] Psoriasis is a common chronic inflammatory dermatitis mediated by cytokines released by dendritic plasmacytoid cells in combination with Th1- and Th17-cells. This complex and multifactorial condition is commonly associated with some comorbidities. The complexity of a coordinated management of such intricated pathologies is obvious. It calls for the so-called medicine "centered around the patient" which tops off the evidence-based medicine. Vitamin D by its immunomodulatory effect on T helper cells exerts a therapeutic benefit on psoriasis and some of its comorbidities including the metabolic syndrome. A vitamin D oral treatment was proposed in order to reduce the cardiovascular risk, and the ensuing morbidity and mortality.
Disciplines :
Dermatology
Author, co-author :
Franchimont, Claudine ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Département des sciences biomédicales et précliniques
Quatresooz, Pascale ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Département des sciences biomédicales et précliniques
PIERARD, Gérald ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie
Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques
Language :
French
Title :
La comorbidite psoriasis-syndrome metabolique, une maladie multigenique complexe.
Alternative titles :
[en] The psoriasis--metabolic syndrome comorbidity, a complex multigenic disease
Publication date :
2012
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Université de Liège. Revue Médicale de Liège, Liège, Belgium
Naldi L, Chatenoud L, Linder D, et al. - Cigarette smoking, body mass index, and stressfull life events as risk factors for psoriasis : results from an Italian case-control study. J Invest Dermatol, 2005, 125, 61-67. (Pubitemid 40981424)
Clark L, Lebwohl M. - The effect of weight on the efficacy of biologic therapy in patients with psoriasis. J Am Acad Dermatol, 2008, 58, 443-446.
Naldi L, Addis A, Chimenti S, et al. - Impact of body mass index on clinical response to systemic treatment for psoriasis. Dermatology, 2008, 217, 365-373.
Esposito M, Mazzotta A, Saraceno R, et al. - Influence and variation of the body mass index in patients treated with etanercept for plaque-type psoriasis. Int J Immunopath Pharmacol, 2009, 22, 219-225.
Lebwohl M, Yielding N, Szapary P, et al. - Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis : rationale for dosing recommendations. J Am Acad Dermatol, 2010, 63, 571-579.
Puig L. - Obesity and psoriasis : body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol, 2011, 25, 1007-1011.
Gottlieb AB, Chao C, Dann F. - Psoriasis comorbidities. J Dermatol Treat, 2008, 19, 5-21.
Piérard GE, Piérard-Franchimont C, Szepetiuk G, et al. - The therapeutic potential of TNFα antagonists for skin psoriasis comorbidities. Expert Opin Biol Ther, 2010, 10, 1197-1208.
Fu LW, Vender R. - Systemic role for vitamin D in the treatment of psoriasis and metabolic syndrome. Dermatol Res Pract, 2011, 2011, 276079. Epub 2011 Jun 5.
Peternel S, Kastelan M. - Immunopathogenesis of psoriasis : focus on natural killer T cells. J Eur Acad Dermatol Venereol, 2009, 23, 1123-1127.
Rorive M, De Flines J, Paquot N, Scheen AJ. - Prise en charge d'une personne obese avec syndrome métabolique. Rev Med Liège, 2009, 64, 651-656.
Sommer DM, Jenisch S, Suchan M, et al. - Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res, 2006, 298, 321-328.
Gisondi P, Tessari G, Conti A, et al. - Prevalence of metabolic syndrome in patients with psoriasis : a hospital-based case-control study. Br J Dermatol, 2007, 157, 68-73. (Pubitemid 46934281)
Azfar RS, Gelfand JM. - Psoriasis and metabolic disease : epidemiology and pathophysiology. Curr Opin Rheumatol, 2008, 20, 416-422.
Gottlieb AB, Dann F, Menter A. - Psoriasis and the metabolic syndrome. J Drugs Dermatol, 2008, 7, 563-572.
Libby P. - Inflammation in atherosclerosis. Nature, 2002, 420, 868-874.
Mehta NN, Azfar RS, Shin DB, et al. - Patients with severe psoriasis are at increased risk of cardiovascular mortality : cohort study using the general practice research database. Eur Heart J, 2010, 31, 1000-1006.
Mottillo S, Filion KB, Genest J, et al. - The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am College Cardiol, 2010, 56, 1113-1132.
Matilainen JM, Husso T, Toropainen S, et al. - Primary effect of 1α, 25 (OH)2D3 on IL-10 expression in monocytes is short-term down-regulation. Biochem Biophys Acta, 2010, 1803, 1276-1286.
McConnell JP, Foley KF, Vargas GM. - Hypovitaminosis D : a new risk marker for cardiovascular disease. Clin Lab Sci, 2009, 22, 240-246.
Ikeda U, Wakita D, Ohkuri T, et al. - 1α,25-dihidroxyvitamin D3 and all-trans retinoic acid synergistically inhibit the differentiation and expansion of Th17 cells. Immunol Lett, 2010, 134, 7-16.
Lehmann B. - Role of the vitamin D pathway in healthy and diseased skin - facts, contradictions and hypotheses. Exp Dermatol, 2009, 18, 97-108.
Abramovits W. - Calcitriol 3 microg/g ointment: an effective and safe addition to the armamentarium in topical psoriasis therapy. J Drugs Dermatol, 2009, 8, S17-S22.
Botella-Carretero JI, Alvarez-Blasco F, Villafruela JJ, et al. - Vitamin D deficiency is associated with the metabolic syndrome in morbid obesity. Clin Nutr, 2007, 26, 573-580. (Pubitemid 47618319)
Mrowietz U, Elder JT, Barker J. - The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients. Arch Dermatol Res, 2006, 298, 309-319.
Kimball AB, Gladman D, Gelfand JM, et al. - National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol, 2008, 58, 1031-1042.